BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2019 9:20:19 AM | Browse: 883 | Download: 1073
 |
Received |
|
2018-10-19 04:44 |
|
Peer-Review Started |
|
2018-10-19 08:53 |
|
To Make the First Decision |
|
2018-11-16 02:18 |
|
Return for Revision |
|
2018-11-28 00:36 |
|
Revised |
|
2018-12-06 18:27 |
|
Second Decision |
|
2019-01-08 11:24 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-01-09 21:31 |
|
Articles in Press |
|
2019-01-09 21:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-01-18 06:26 |
|
Publish the Manuscript Online |
|
2019-01-21 09:20 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ammar B Nassri, Valery Muenyi, Ahmad Alkhasawneh, Bruno De Souza Ribeiro, James S Scolapio, Miguel Malespin and Silvio W de Melo Jr |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ammar B Nassri, MD, Academic Fellow, Department of Medicine; Division of Gastroenterology and Hepatology, University of Florida at Jacksonville, 655 W 8th St, Jacksonville, Florida 32209, United States. anassri@gmail.com |
| Key Words |
Colitis; Infliximab; Biologics; Immune mediated adverse events; Ipilimumab; Nivolumab; Case report |
| Core Tip |
A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events. We report the first case of metastatic renal cell cancer treated with the anti-CTLA-4 monoclonal antibody Ipilimumab and the immune checkpoint inhibitor Nivolumab to develop severe steroid-refractory colitis, and describe its resolution after treatment with Infliximab. |
| Publish Date |
2019-01-21 09:20 |
| Citation |
Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BDS, Scolapio JS, Malespin M, de Melo Jr SW. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report. World J Gastrointest Pharmacol Ther 2019; 10(1): 29-34 |
| URL |
https://www.wjgnet.com/2150-5349/full/v10/i1/29.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v10.i1.29 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
